CSIMarket
 
Pds Biotechnology Corp  (PDSB)
Other Ticker:  
 
 
Price: $4.7550 $-0.15 -2.959%
Day's High: $4.9 Week Perf: 2.81 %
Day's Low: $ 4.67 30 Day Perf: -12.91 %
Volume (M): 352 52 Wk High: $ 10.27
Volume (M$): $ 1,675 52 Wk Avg: $5.59
Open: $4.89 52 Wk Low: $3.80



 Market Capitalization (Millions $) 147
 Shares Outstanding (Millions) 31
 Employees 20
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -51
 Cash Flow (TTM) (Millions $) -17
 Capital Exp. (TTM) (Millions $) 0

Pds Biotechnology Corp
Pds Biotechnology Corp is a clinical-stage biotechnology company located in New Jersey, USA, founded in 200 The company aims at developing immunotherapy-based treatments for cancer and infectious diseases by using its unique Versamunee platform technology.

The Versamunee platform technology combines lipids with peptides to produce an immunostimulatory molecule that effectively triggers and augments T-cell responses against specific antigens. This mechanism of action renders Versamunee an excellent candidate as an immunotherapeutic vaccine adjuvant for combating both solid tumor and viral indications.

The company's pipeline includes multiple immunotherapeutic products in clinical development for the treatment of head and neck cancer, prostate cancer, human papillomavirus (HPV)-associated cancers, and COVID-19. Its lead candidate, PDS0101, is a cancer immunotherapy that uses Versamunee as an adjuvant to elicit a potent anti-tumor T-cell response.

In December 2020, Pds Biotechnology announced positive interim results from a Phase 2 trial of PDS0101 in combination with Keytrudae (pembrolizumab) for the treatment of HPV-positive head and neck cancer. The company reported excellent response rates, with an objective response rate of 67% in patients who had failed previous treatment with chemotherapy and radiation.

Pds Biotechnology has also developed PDS0203, a COVID-19 vaccine candidate, using Versamunee as an adjuvant. The vaccine candidate has shown promising preclinical results, with a strong immune response against SARS-CoV-2 in animal models.

In addition to these clinical and preclinical assets, Pds Biotechnology has entered into partnerships with larger pharmaceutical companies, such as Merck & Co, for the clinical development of its immunotherapeutic products. These partnerships provide additional financial resources and research expertise to the company, further advancing its clinical portfolio.

Overall, Pds Biotechnology is leading the charge in developing innovative immunotherapies that have the potential to revolutionize cancer and infectious disease treatment. With its robust pipeline and proven Versamunee platform technology, the company is well-positioned to make significant strides in the biotechnology industry in the coming years.


   Company Address: 303A College Road East Princeton 8540 NJ
   Company Phone Number: 208-3343   Stock Exchange / Ticker: NASDAQ PDSB
   PDSB is expected to report next financial results on March 27, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

PDS Biotechnology Grants Inducement Stock Options to Newly Appointed CFO, Reinforcing Commitment to Strategic Growth

Published Mon, Dec 4 2023 9:50 PM UTC

PDS Biotechnology Grants Inducement Stock Options to New CFO Lars Boesgaard
PRINCETON, N.J., Dec. 04, 2023 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company specializing in targeted immunotherapies for cancer and infectious diseases, has recently announced the grant of nonstatutory stock options to Lars Boesgaard, the Company's new Ch...

Pds Biotechnology Corp

Reimagined Headline: Pds Biotechnology Corp Witnesses Substantial Surge in Working Expenditures During the Closing Financial Period of September 30, 2023

Pds Biotechnology Corp: A Bearish Outlook on the Pharmaceutical Industry
In the ever-evolving world of pharmaceutical preparations, Pds Biotechnology Corp seems to be facing significant challenges as it enters the third quarter of 2023. Despite the positive outlook expressed by the company in its recent financial results announcement, a closer look reveals concerning trends that may raise doubts about Pds Biotech's ability to compete in this highly competitive industry.
First and foremost, Pds Biotechnology Corp reported an operating shortfall of $-10.519686 million for the July to September 2023 financial reporting period. This represents a substantial increase from the operating shortfall of $-7.279196 million in the same period of the previous year. This widening gap suggests that the company's operations are becoming increasingly inefficient, unable to generate sufficient revenue to cover its expenses.

Pds Biotechnology Corp

Deterioration in PDS Biotechnology Corp's Performance Raises Concerns for Future Prospects



The financial results of Pds Biotechnology Corp's second quarter of 2023 have attracted significant attention from researchers in the Major Pharmaceutical Preparations sector. While the operating loss has contracted from the previous year, the absence of any top-line mention raises questions about the company's future prospects. As the management seeks new financial strategies to ensure consistent revenue streams, it remains to be seen how these shortfalls and the upcoming financial reports will impact Pds Biotechnology Corp.
1. Operating Loss Contractions:
Pds Biotechnology Corp reported an operating loss of $-12.696173 million for the second quarter of 2023, an increase from the previous year's operating loss of $-7.092652 million. Although the losses have widened, the contraction suggests that the company may be taking steps to address its financial performance.

Pds Biotechnology Corp

Pds Biotechnology Corp Faces Rising Costs in Q1 2023, Yet Continues to Impress Investors with its Growth Potential

Pds Biotechnology Corp, a rising corporation in the biotechnology industry, has recently faced some challenges during the earnings season of January to March 31, 2023. The shareholders were not expecting any changes in the company during this period, however, they paid close attention to PDSBs' operating shortfall that was at $-9.422414 million in the same period. Despite this setback, Pds Biotechnology Corp has shown great potential in its early stages and has garnered the attention of investors and industry experts.
PDSBs has not yet reported its revenue, but to put its latest conduct into context, it is important to compare it to its corporate achievement through the first quarter of 2022, where the company announced an operating shortfall of $-8.479222 million. It is unsurprising that the company reported a shortfall of $-9.660 million, which has expanded from $-8.474 million in the same three months a year before. The company's growth has been impressive, however, it is important to keep an eye on its operating shortfall and take corrective measures.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com